Process for preparing high-purity dematan sulphate, and pharmaceutical
compositions which contain it
    2.
    发明授权
    Process for preparing high-purity dematan sulphate, and pharmaceutical compositions which contain it 失效
    制备高纯度硫酸阿坦丹的方法和含有它的药物组合物

    公开(公告)号:US4870166A

    公开(公告)日:1989-09-26

    申请号:US27733

    申请日:1987-03-19

    CPC分类号: C08B37/0069

    摘要: A process for preparing dermatan sulphate (DS) of pharmaceutical purity from animal organs rich in mucopolysaccharides (MPS), by: (a) stabilizing the fresh organs by freezing them either as such or in the form of powder, (b) micronizing the material containing the MPS with an aqueous CaCl.sub.2 solution, (c) digesting the homogenate comprising the raw material and the CaCl.sub.2 with proteolytic enzymes at alkaline pH and at low temperature, (d) acidifying, heating and filtering the lysate, (e) treating the filtrate with quaternary ammonium salts able to undergo complexing with and thus precipitate either the DS along or all the MPS selectively, (f) recovering and purifying the DA either directly from the ammonium salt complex containing it or from the complex obtained from the mixture of ammonium salt complexes of all the MPS by fractional solubilization with acetone.

    摘要翻译: 通过以下方式,从富含粘多糖(MPS)的动物器官制备药物纯度的硫酸皮肤素(DS)的方法:(a)通过如下或以粉末形式使新鲜的器官冷冻来稳定新鲜器官,(b)使材料微粉化 (c)在碱性pH和低温下用蛋白水解酶消化含有原料和CaCl 2的匀浆,(d)酸化,加热和过滤裂解物,(e)处理滤液 其中季铵盐能够与MPS选择性地沿着或所有的MPS进行络合并从而沉淀DS,(f)直接从含有它的铵盐络合物或从得自铵盐混合物的络合物中回收和纯化DA 通过与丙酮分解溶解所有MPS的复合物。

    Process for producing natural heparan sulphate and dermatan sulphate in
substantially pure form, and their pharmaceutical use
    3.
    发明授权
    Process for producing natural heparan sulphate and dermatan sulphate in substantially pure form, and their pharmaceutical use 失效
    用于生产基本纯净形式的天然硫酸乙酰肝素和硫酸皮肤素的方法及其药物用途

    公开(公告)号:US4783447A

    公开(公告)日:1988-11-08

    申请号:US838133

    申请日:1986-03-10

    摘要: A process for producing natural heparan sulphate and dermatan sulphate for mixtures of proteoglycans from the aorta, myocardium and particularly vascularized organs, based on a series of precipitation and purification steps which enable the protein part of the proteoglycan to be eliminated and the two products to be obtained in substantially pure form, without any chemical or enzymatic degradation.When administered orally or parenterally, the heparan sulphate obtained exerts activation effects on antithrombin III and on the fibrinolytic process.The dermatan sulphate obtained exerts an inhibiting effect on Factor Xa and also possesses the property of activating the fibrinolytic effect of heparan sulphate.

    摘要翻译: 基于一系列沉淀和纯化步骤,可以消除蛋白多糖的蛋白质部分和两种产物,从而制备天然硫酸乙酰肝素和硫酸皮肤素用于来自主动脉,心肌和特别是血管化器官的蛋白聚糖混合物的方法 以基本上纯的形式获得,没有任何化学或酶降解。 当口服或肠胃外给药时,获得的硫酸乙酰肝素对抗凝血酶III和纤维蛋白溶解过程产生活化作用。 所得硫酸皮肤素对因子Xa具有抑制作用,并具有激活硫酸乙酰肝素的纤维蛋白溶解作用的性质。

    Process for the controlled preparation of low molecular weight
glucosaminoglycans
    4.
    发明授权
    Process for the controlled preparation of low molecular weight glucosaminoglycans 失效
    用于控制制备低分子量葡糖胺聚糖的方法

    公开(公告)号:US4987222A

    公开(公告)日:1991-01-22

    申请号:US120953

    申请日:1987-11-16

    摘要: A process for the controlled preparation of low molecular weight glucosaminoglycans by treating conventional high molecular weight glucosaminoglycans in the solid state or in solution form with a rectilinear gamma ray beam at doses within the range of 2.5 to 20 Mrad supplied by successive irradiation stages with cooling intervals between one irradiation stage and the next in the dynamic phase.The mixture obtained is subjected to fractionation, purification, neutralization and lyophilization. The glucosaminoglycans obtained have a molecular weight of between 1000 and 35,000 daltons and are used for the preparation of pharmaceutical compositions possessing antithrombotic, fibinolytic, antiatherogenic and heparin cofactor II activation activity.

    摘要翻译: 通过用连续照射阶段提供的剂量在2.5至20Mrad范围内的剂量处理固体状态或溶液形式的常规高分子量葡糖胺聚糖与冷却间隔来控制制备低分子量葡糖胺聚糖的方法 在一个辐射阶段和下一个在动态阶段之间。 将得到的混合物进行分馏,纯化,中和和冻干。 获得的葡糖胺聚糖具有1000至35,000道尔顿之间的分子量,并且用于制备具有抗血栓形成,纤维蛋白溶解,抗动脉粥样化和肝素辅因子II活化活性的药物组合物。

    PROCESS FOR THE PURIFICATION OF HEPARAN SULFATE AND USE THEREOF IN COSMETOLOGICAL AND DERMATOLOGICAL PREPARATIONS
    5.
    发明申请
    PROCESS FOR THE PURIFICATION OF HEPARAN SULFATE AND USE THEREOF IN COSMETOLOGICAL AND DERMATOLOGICAL PREPARATIONS 有权
    硫代硫酸盐的净化方法及其在化学和制药领域的应用

    公开(公告)号:US20110288047A1

    公开(公告)日:2011-11-24

    申请号:US13129030

    申请日:2009-09-29

    申请人: Luigi De Ambrosi

    发明人: Luigi De Ambrosi

    摘要: The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the resin by using conditions which result in selective desorption of hepar an sulfate. The cosmetological and dermatological compositions according to the invention show, inter alia, anti-age, lenitive, and whitening effect.

    摘要翻译: 本发明涉及包含硫酸乙酰肝素的美容和皮肤病学组合物。 本发明还公开了一种用于皮肤病学和美容应用的硫酸乙酰肝素的纯化方法,该方法包括以下步骤:将硫酸乙酰肝素溶解于水中,在阴离子交换树脂上吸附,通过使用导致选择性的条件从树脂中解吸 肝素硫酸盐解吸。 根据本发明的美容和皮肤病学组合物尤其表现出抗衰老,延缓和美白效果。

    Extracting protease-inhibitor from animal tissue containing same
    9.
    发明授权
    Extracting protease-inhibitor from animal tissue containing same 失效
    从含有它的动物组织中提取蛋白酶抑制剂

    公开(公告)号:US4216293A

    公开(公告)日:1980-08-05

    申请号:US916536

    申请日:1978-06-19

    CPC分类号: C08B37/0066 C07K14/8117

    摘要: Protease inhibitor is extracted from fresh or frozen organs of slaughtered animals by an enzymolysis operation which excludes any possibility of interference by azymic autolysis, the enzymolysis being stopped after a time not exceeding 4 hours, whereafter a lysate aqueous solution is obtained by filtration and a quaternary ammonium base is added to the lysate solution to precipitate insolubles, the filtrate being the fraction which contains the expected protease inhibitor.

    摘要翻译: 通过酶解操作从屠宰动物的新鲜或冷冻器官中提取蛋白酶抑制剂,其排除任何可能的干扰自由酶的可能性,在不超过4小时的时间后停止酶解,然后通过过滤获得裂解物水溶液, 将铵碱加入裂解液中以沉淀不溶物,滤液为含有预期蛋白酶抑制剂的级分。